Spectral AI Appoints Dr. J. Michael DiMaio to Board of Directors
The Company’s two largest stockholders holding approximately 45% of the Company’s outstanding shares have extended their lock-up agreements for an...
The Company’s two largest stockholders holding approximately 45% of the Company’s outstanding shares have extended their lock-up agreements for an...
Approval triggered by positive results from ReSTORE Phase III clinical trialPayment will advance Cidara’s Cloudbreak platform for the development of...
4D-310 demonstrated clinically meaningful cardiac endpoint improvements through 12-24 months in contractility (echocardiography), peak VO2 (cardiopulmonary exercise testing) and/or cardiac...
Designation for BXCL701 in combination with a checkpoint inhibitor (CPI) for treatment of patients with metastatic SCNC with progression on...
Independent Research Confirms >$10bn Market Opportunity for POLB 001 as a Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)Former...
The FDA has accepted a New Drug Application filed by Lykos Therapeutics for MDMA-assisted therapy for PTSD The application was...
MacNaughton to Lead Business into Enterprise-first EraNEW YORK--(BUSINESS WIRE)--Please replace the release dated February 8, 2024 with the following corrected...
PharmAla will consult on GMP Drug Product and Regulatory Development for Red Light Holland Toronto, Ontario--(Newsfile Corp. - February 9,...
Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage...
PharmAla will consult on GMP Drug Product and Regulatory Development for Red Light HollandVANCOUVER, British Columbia, Feb. 09, 2024 (GLOBE...
– BLA submission supported by results from Phase 2/3 clinical trial and outcomes of real-world use of the HAV under...
News of the Successful Trial Comes Amid an Oversubscribed Investor Round and Preparation for Series A Financing RoundRALEIGH, NC /...
MacNaughton to Lead Business into Enterprise-first Era, with OptumRx as Strategic PartnerNEW YORK--(BUSINESS WIRE)--Calibrate, the leading clinician-guided and value-based obesity...
NASHVILLE, TN / ACCESSWIRE / February 8, 2024 / Profound Research, a leading clinical trial site network, today announced key...
IRVING, Texas--(BUSINESS WIRE)--For the eighth consecutive year, McKesson has received approval from the Centers for Medicare & Medicaid Services (CMS)...
IRVING, Texas--(BUSINESS WIRE)--For the eighth consecutive year, McKesson has received approval from the Centers for Medicare & Medicaid Services (CMS)...
JACKSON CENTER, PA / ACCESSWIRE / February 8, 2024 / Halberd Corporation's (OTC PINK:HALB) Traumatic Brain Injury (TBI) mitigating nasal...
ANN ARBOR, MI / ACCESSWIRE / February 8, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary...
• Initial clinical data suggest the potential of B-VEC to treat lesions in the eye of DEB patients and additional...
– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and...